mProX™ Human MAPK13 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX413	Magic™ Human p38δ(MAPK13) in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;HEC-1

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Colorectal Cancer

Gene ID

Human:5603

UniProt ID

Human:O15264

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

MAPK13, also known as p38Œ≥, is a kinase that plays a role in various biological processes, including inflammation and immune response. In respiratory airway diseases, MAPK13 is activated and required for mucus production. Researchers have developed a potent MAPK13-14 inhibitor that effectively down-regulates mucus production and prevents airway inflammation in models of airway disease. In diffuse large B-cell lymphoma, MAPK13 has been found to be expressed more than four-fold in a rituximab-resistant cell line, suggesting an association between MAPK13 activation and rituximab resistance. In cancer cells, m6A modification of MAPK13 mRNA determines the sensitivity to rapamycin, an mTORC1-targeting agent. MAPK13 stabilization limits the anticancer efficacy of rapamycin. Additionally, MAPK13, along with p38Œ¥, has been found to modulate innate immune response by regulating the activation of the transcription factor MEF2D. These studies indicate that MAPK13 has potential applications in the treatment of respiratory diseases, lymphomas, cancer, and modulation of the immune response.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human MAPK13 Stable Cell Line (S01YF-1023-PY38). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jordan Jones (Verified Customer)

How does MAPK13 modification affect cancer cell sensitivity to rapamycin? Feb 28 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

m6A modification of MAPK13 mRNA plays a crucial role in determining the sensitivity of cancer cells to the chemotherapeutic agent rapamycin. Feb 28 2022

chat Alex Miller (Verified Customer)

What is the significance of MAPK13 in endometrial carcinoma? Jan 07 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

The circTNFRSF21-miR-1227-MAPK13/ATF2 axis has been identified as a promising target for endometrial carcinoma treatment. Jan 07 2022

Published Data

Fig.1 MAPK13 is involved in Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) maintenance.

Using the Aldefluor assay, ALDH activity of MAPK13 knockdown cells was found 48 hours after transfection (right panel). The percentage indicates the fraction of cells with ALDH1 high content. These findings suggest that MAPK13 may be involved in CSCs/CICs maintenance.

Ref: Yasuda, Kazuyo, et al. "MAPK13 is preferentially expressed in gynecological cancer stem cells and has a role in the tumor-initiation." Biochemical and Biophysical Research Communications 472.4 (2016): 643-647.

Pubmed: 26969274

DOI: 10.1016/j.bbrc.2016.03.004

Research Highlights

P Keeler, Shamus. et al. "A potent MAPK13-14 inhibitor prevents airway inflammation and mucus production." American journal of physiology. Lung cellular and molecular physiology, 2023.
Research has shown that respiratory diseases remain a significant public health concern, with a prominent source of illness and death being airway inflammation and mucus production. While past research has suggested the role of mitogen-activated protein kinase 14 (MAPK14) in these conditions, attempts at clinical trials have been unsuccessful. Furthermore, our initial investigations revealed the involvement of a similar yet separate kinase, MAPK13, in respiratory airway diseases and the crucial role it plays in mucus production within human cell-culture models. The efficacy of MAPK13 was demonstrated through experimental support in these models.
P Keeler, Shamus. et al. "A potent MAPK13-14 inhibitor prevents airway inflammation and mucus production." American journal of physiology. Lung cellular and molecular physiology, 2023.
Pubmed: 37847710 DOI: 10.1152/ajplung.00183.2023

Ji Jeon, Min. et al. "Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing." The Korean journal of internal medicine, 2023.
Despite success in treating diffuse large B-cell lymphoma, rituximab resistance poses a continuing obstacle for clinicians. This issue persists despite the effectiveness of rituximab, an anti-CD20 monoclonal antibody.
Ji Jeon, Min. et al. "Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing." The Korean journal of internal medicine, 2023.
Pubmed: 37599392 DOI: 10.3904/kjim.2023.134